Orthoclone OKT3 is a very powerful immunosuppressive drug marketed by Laboratory Cilag
and the first monoclonal murine antibody to become available for therapy in humans. It is
indicated in acute allograft rejection treatment and its side-effects are strongly linked with its
mechanism of action. ORT/OKT3 is an Ig2a immunoglobulin produced by hybridoma
technique that recognizes, binds and blocks the CD3 complex of the T-cell receptor. Two
types of side-effects may occur that are either the consequences of overimmunosuppression …